EXTON, Pa. & PHILADELPHIA--(BUSINESS WIRE)--Adolor Corporation (NASDAQ:ADLR) and GlaxoSmithKline (NYSE:GSK) announced today that the Phase 3 Study 14CL314 of ENTEREG® (alvimopan) for the management of postoperative ileus (POI) has been published in the November issue of Archives of Surgery, the official publication of the New England Surgical Society, the Pacific Coast Surgical Association and the Western Surgical Association. This study demonstrated that ENTEREG accelerated the time to recovery of gastrointestinal (GI) function, shortened length of hospital stay and reduced POI-related morbidity following bowel resection surgery in the patients studied.
